Segment Information

3 Months Ended

Apr. 01, 2017

SEGMENT INFORMATION

Effective January 1, 2017, in addition to the segment change in the fourth quarter of 2016, we implemented certain changes to our reporting segments following the sale of the Tysabri^® royalty stream. As a result, beginning in the first quarter of fiscal year 2017, our reporting segments consist of CHCA, CHCI, RX and Other.

Our reporting segments are as follows:


•	CHCA, comprises our U.S., Mexico and Canada consumer healthcare business (OTC, contract, infant formula and animal health categories).


•	CHCI, comprises our legacy Branded Consumer Healthcare segment and now includes our consumer focused businesses in the U.K., Australia, and Israel. This segment also includes our U.K. liquid licensed products business.


•	RX, comprises our U.S. Prescription Pharmaceuticals business.

We also have an Other reporting segment that consists of our API business, which does not meet the quantitative threshold required to be a separately reportable segment. Our segments reflect the way in which our chief operating decision maker reviews our operating results and allocates resources.

The below tables show select financial measures by reporting segment (in millions):



Total Assets	April 1, 2017		December 31, 2016
CHCA	$	6,295.7	$	3,351.3
CHCI	4,796.9		4,795.2
RX	2,685.4		2,646.4
Specialty Sciences	—		2,775.8
Other	201.4		301.4
Total	$	13,979.4	$	13,870.1



	Three Months Ended
	April 1, 2017							April 2, 2016
	Net Sales		Operating Income (Loss)			Intangible Asset Amortization		Net Sales		Operating Income (Loss)			Intangible Asset Amortization
CHCA	$	582.8	$	75.0		$	17.1	$	639.1	$	100.6		$	18.1
CHCI	374.9		0.2			45.7		439.4		(396.4		)	41.2
RX	217.4		88.2			22.3		248.2		91.4			25.5
Specialty Sciences	—		—			—		—		(1.4		)	—
Other	18.9		5.7			0.4		20.6		5.5			0.5
Unallocated	—		(40.6		)	—		—		(31.3		)	—
Total	$	1,194.0	$	128.5		$	85.5	$	1,347.3	$	(231.6	)	$	85.3